Chairman and Co-Chief Executive Officer, Guardant Health, Inc.
Search every verified Helmy Eltoukhy interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Helmy Eltoukhy, chairman and co-CEO of Guardant Health, appeared in several media interviews in September 2026 to discuss the FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in advanced breast cancer. On CNBC’s Squawk on the Street, he described the approval as a "landmark change" in cancer management, explaining that the blood-based test allows physicians to monitor tumor mutations every three months and detect early signs of molecular resistance, potentially enabling earlier treatment changes. He noted that the test was developed about a decade ago and represents a shift from invasive tissue biopsies to liquid biopsy. On CNN’s The Situation Room, he said the approval could represent "the future of cancer care" and cited clinical trial data showing the treatment lowered the risk of disease progression or death by 56% for certain breast, colon, and lung cancers. He also stated that Guardant360 is covered for over 300 million lives in the U.S. and that the UK’s NHS adopted the test for lung cancer patients. In a separate podcast conversation with South Park Commons Partner Mark Jacobstein, Eltoukhy discussed Guardant’s broader strategy, describing the company’s mission as "conquering cancer with data" and outlining three business areas: late-stage cancer patients, cancer survivors, and early cancer detection, which he said represent addressable markets of $10 billion, $20 billion, and $50 billion respectively. He also discussed the difficulty of building a diagnostics business due to regulatory approvals and reimbursement, and mentioned that the company once scrapped an early version of its technology that was not scalable. He expressed interest in expanding beyond oncology, suggesting the blood test could eventually detect "hundreds if not thousands of diseases," and emphasized the importance of ensuring access to testing for disadvantaged populations, stating the company avoided a "concierge" business model for multicancer early detection because "bending mortality curves means testing everyone."
Our Chairman and Co-CEO Helmy Eltoukhy joins CNBC’s Squawk on the Street to discusses the landmark FDA approval of Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in advanced breast cancer and how liquid biopsy can help physicians monitor tumor mutations to inform treatment decisions. Originally Aired: September 25, 2026
What if one blood test could detect hundreds or even thousands of diseases? Guardant Health CEO Helmy Eltoukhy joins South Park Commons Partner Mark Jacobstein to explain how that vision could become possible. They trace Guardant’s journey from liquid biopsy to early cancer detection, the difficult decisions that shaped the company along the way, and why diagnostics is such a uniquely hard business to build. Helmy also breaks down how AI is accelerating Guardant’s ability to analyze its data and opening the door to new applications far beyond cancer. 1. Helmy Eltoukhy: / helmy-eltoukhy-b…
In a CNN The Situation Room interview, Guardant Health Co-CEO Helmy Eltoukhy joins Pamela Brown to share how a blood test can monitor tumor mutations and help inform treatment decisions for certain patients with advanced breast cancer. He discusses a first-of-its-kind FDA approval and what it could mean for the future of more precise, proactive cancer care.
Our Chairman and co-CEO, Helmy Eltoukhy, joins FOX Business to discuss Guardant Health's strong second-quarter 2026 results, the rapid adoption of Shield™ blood-based colorectal cancer screening test, and how Guardant's AI-powered platform is advancing cancer care. Helmy also shares how Guardant® is expanding blood-based testing beyond a single cancer to multi-cancer detection, the company's long-term vision for multi-disease screening, and why AI and large-scale genomic data are transforming the future of precision medicine. Segment originally aired on FOX Business: July 31, 2026
Guardant Health co-founder and co-CEO Helmy Eltoukhy discusses his company’s blood test for colorectal cancer on ‘The Claman Countdown.’ #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #guardanthealth #helmyeltoukhy #eltoukhy #colorectalcancer #cancer #bloodtest #cancerscreening #healthcare #medicaltechnology #biotechnology #earlydetection #medicalresearch #innovation #healthnews Subscribe to Fox Business: https://bit.ly/2D9Cdse Watch more Fox Business Video: https://video.foxbusiness.com Watch Fox Business Network Live: http://www.foxnewsgo.com/ FO…
Breakthrough blood tests that can flag dozens of cancers before symptoms appear are gaining momentum, yet questions remain about accuracy, equity, and how these tools will fit into routine care. In this episode, Steve talks with Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, a $14 billion publicly-traded precision oncology company. The conversation explores the science behind cell-free DNA, the rise of blood-based cancer screening, and the broader shift toward data-driven diagnostics. We cover: How liquid biopsy works and why cell-free DNA became such a powerful tool The path from l…
At the United Nations’ 11th International Day of Women & Girls in Science Assembly, Guardant Health chairman and co-CEO Helmy Eltoukhy shared a clear message: the future of healthcare depends on shifting from reacting to symptoms to acting on signals.
A session on "Unlocking the Future of Predictive Health with a Simple Blood Test" led by Helmy Eltoukhy (CEO, Guardant Health), moderated by Ayah Hamdan (Director of Health, Plug and Play Ventures).
Our Chairman and co-CEO, Helmy Eltoukhy, joins Bloomberg’s Carol Massar and Romaine Bostick at the Milken Institute Global Conference 2025 to discuss how the Guardant is using blood-based testing powered by DNA sequencing and AI to detect cancer earlier, reduce diagnosis time, and ultimately lower healthcare costs. Segment originally aired on Bloomberg News: May 4, 2025
What if a simple blood test at your annual physical could detect cancer in its earliest stages? Dr. Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, is turning this vision into reality. They’ve seen a spate of FDA approvals. With groundbreaking technologies like Guardant360 and Shield, they're revolutionizing cancer detection and treatment. By harnessing genomics and epigenomics, Guardant's tests can identify cancer signals in the blood, even before symptoms appear. Adil Ali, reporting for Onyx, caught up with Helmy at JPM Week 2025.
Green Sands Equity CEO Reema Khan discussed some exciting healthcare diagnostics innovations with Guardant Health Co-founder, Chairman, and co-CEO Dr. Helmy Eltoukhy and Co-founder and co-CEO AmirAli Talasaz. #HEF2024 #UNGA79 #healthequity #HealthEquityForum #PublicHealth #GlobalHealth #innovation #healthcareinnovation
To tackle cancer, we first need to identify it. Many cancers, if found early, have a survival rate of at least 90 percent. However, 65 percent of Americans are not up to date on at least one of their routine cancer screenings. Revolutionary cancer screening technologies entering the market are designed to take account of patient preferences and potentially expand access to, and decrease the inconvenience and discomfort of, conventional cancer screening tests. Innovative technologies—such as smart patches that can detect melanoma without an incision, a quick blood test to detect colorectal canc…
Sign in to search the full transcript archive, filter by topic, and access every quote from Helmy Eltoukhy.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans